Search Results

CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236.

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company.

CERo Therapeutics Holdings, Inc., announces it is presenting preclinical data on its lead product candidate CER-1236 at the Stanford Drug Discovery Symposium, which is being held April 29-30, 2024 in Palo Alto, Calif.

CERo Therapeutics Holdings, Inc., today announced the publication in Clinical Cancer Research , a journal of the American Association for Cancer Research, a paper titled “ Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia.”

CERo Therapeutics, Inc. (“CERo”) and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (“PBAX”), a special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, today announced they have entered into a definitive business combination agreement.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

CERo Therapeutics, Inc., today announced new preclinical data to be presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) demonstrating significant anti-tumor effects of chimeric engulfment receptor (CER) T cells when combined with small molecule therapies in both hematologic and solid tumor models.

CERo Therapeutics, Inc., a biopharmaceutical company pioneering the development of novel autologous engineered immune cell therapies, presented the results from preclinical in vitro studies describing the characterization of novel chimeric engulfment receptor T cells.

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.